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Factors involved in the anti-cancer activity of the investigational agents
LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid)
M.C. Bibby, J.A. Double, R.M. Phillips & P.M. Loadman
Clinical Oncology Unit, University ofBradford, Bradford BD7 JDP, UK.
Summary LM985 has been shown previously to hydrolyse to flavone acetic acid (LM975) in mouse plasma
and to produce significant anti-tumour effects in transplantable mouse colon tumours (MAC). It has
undergone Phase I clinical trials and dose limiting toxicity was acute reversible hypotension. Substantially
higher doses of LM975 can be given clinically without dose limiting toxicity. We have investigated the activity
of LM975 against a panel of MAC tumours and also the in vitro cytotoxicity of both LM985 and LM975 in
two cell lines derived from MAC tumours. LM985 is considerably more cytotoxic than LM975 in vitro but
increased length of exposure to LM975 results in improved activity. Single in vivo injection of LM975 showed
no activity against the ascitic tumour MAC 15A, moderate activity against the s.c. poorly differentiated
tumour MAC 13 and produced a significant growth delay in the well differentiated MAC 26. These latter
responses were considerably enhanced by repeated injection 7 days later. Pharmacokinetic studies in mice
following i.p. injection of LM985 demonstrated rapid degradation of LM985 to LM975 in the peritoneum.
Length of exposure as well as drug concentration appear important factors in determining anti-tumour
responses.
4H-1-benzopyran-8-acetic acid, 4 oxo-2-phenyl-,2- (diethyl-
amino) ethylester hydrochloride (Figure IA) was selected for
Phase I clinical evaluation largely on its activity against
colon 38 in the NCI screen. Double et al. (1986) have
demonstrated significant activity against mouse trans-
plantable subcutaneous colon tumours (MAC) and also
confirmed the rapid hydrolysis of LM985 to flavone acetic
acid (LM975) (Figure 1B) suggested by Kerr et al. (1985).
There was a good dose relationship between plasma levels of
LM975 and the administered dose of LM985 and a clear
relationship between areas under the curve and tumour
responses. An ascitic colon tumour failed to respond to
treatment suggesting tumour site may be an important
factor.
Kerr et al. (personal communication) have commenced a
Phase I clinical study with LM975 and they state that
substantially higher doses of the hydrolysis product can be
given without dose-limiting cardiovascular toxicity. Recently
Plowman et al. (1986) have demonstrated regression of
advanced colon 38 tumours by LM975, with greatest efficacy
observed following administration of high individual doses
rather than high total dose.
The present study examines the activity of flavone acetic
acid against three MAC tumour lines. It also describes an in
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Figure 1 Structural formulae of (A) LM985 and (B) LM975.
vitro colony forming assay with MAC lines and examines
their chemosensitivity to LM985 and LM975 in vitro.
Optimal exposure times are assessed and related to
pharmacokinetic profiles and responses achieved in vivo in
order to predict plasma exposures likely to be required for
anti-tumour activity in man.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) from our inbred
colony were used. They were fed on CRM diet (Labsure,
England) and water ad libitum.
Test compounds
LM985 was received from the EORTC Screening & Pharma-
cology Group and further supplies were a gift from Dr W.R.
Vezin, CRC Formulation Unit, University of Strathclyde.
LM975 was a gift from Lipha (Lyon) via Professor S.B.
Kaye, University of Glasgow. Positive control compounds
methyl-CCNU and cyclophosphamide were gifts from the
NCI and Boehringer, UK, respectively. For in vivo experi-
ments LM975, LM985 and cyclophosphamide were dissolved
in physiological saline and methyl-CCNU in 10%
ethanol/arachis oil at an appropriate concentration for a
desired dose to be administered in 0.1 ml per lOg body
weight. All injections were i.p.
Tumour system
The development of several adenocarcinomata of the large
bowel in NMRI mice from primary tumours induced by
prolonged administration of 1,2-dimethylhydrazine has been
described elsewhere (Double et al., 1975).
In vivo studies MAC 13 and MAC 26 tumours were
transplanted into female mice and MAC 26 tumours into
male mice by s.c. implantation of tumour fragments
(-I x 2mm) in the flank. MAC 15A ascites tumours were
transplanted into male mice by i.p. inoculation of 1 x 106
tumour cells in 0.2ml physiological saline. This inoculation
gives a survival time of - 14 days.
In vitro studies The s.c. solid tumours MAC 13 were
removed aseptically from the inguinal region of the mice and
placed in a small volume of sterile RPMI 1640 medium
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(Flow Laboratories) supplemented with 10% heat inacti-
vated foetal calf serum (FCS) (56°C, 20min), 1 mM sodium
pyruvate, penicillin and streptomycin (50IUml-1). The
ascites tumour MAC 15A was removed by aseptic peritoneal
washing using 5ml supplemented RPMI 1640. 'Primary'
solid tumours were dissected into small pieces (-2mm3) and
transferred into 75ml culture flasks (Corning) containing
30ml supplemented RPMI 1640. Flasks were gassed using a
5% CO2. 95% air mixture, labelled and incubated horizon-
tally at 37°C. The 'primary' ascites tumour suspension was
poured into similar flasks and similarly treated.
Chemosensitivity
In vivo studies The anti-tumour activity of LM985 against
MAC 13, MAC 26 and MAC 15A has been described
previously (Double et al., 1986). The activity of LM975
against these tumours was assessed by using the same
protocols. Chemotherapy commenced 2 days after implan-
tation for MAC 13 and MAC 15A tumour bearers and 21
days after implantation for MAC 26 tumour bearers. MAC
13 tumours were assessed 14 days later by recording tumour
weights and MAC 15A tumours were assessed from median
survival times (Geran et al., 1972). MAC 26 tumours were
assessed by twice weekly two-dimensional caliper measure-
ments. Activity scores for LM975 and positive control
compounds against each tumour line, were allocated by the
method of Double et al., (1986).
In vitro studies Treatment effects of the drugs were assessed
using a clonogenic assay (Hamburger & Salmon, 1977).
Single cell suspensions, derived from primary monolayer
cultures, were exposed to increasing drug concentrations for
different time course exposures at 37°C in RPMI 1640
supplemented with 10% heat inactivated FCS penicillin/
streptomycin (50IUml -1). sodium pyruvate (50 pgml -1).
Following treatment, the cells were washed twice in Hanks'
balanced salt solution and 0.5 x 105 viable cells were plated
into 25ml tissue culture flasks containing 10ml of complete
RPMI 1640. After 5-7 days incubation at 37°C, colonies of
.50 cells were counted using an inverted microscope and
plating efficiencies (MAC 13=4.12%, MAC 15A=6.8%)
calculated for each drug concentration. Cytotoxic effects of
drug treatment were expressed in terms of % survival taking
the control plating efficiency to represent 100% survival for
each experiment. Duplicate samples for each drug concen-
tration were performed.
Measurement ofdrug levels in plasma, the peritoneum and
tissue culture medium
Reagents Spectroscopic grade ethanol (BDH Chemical,
Poole, Dorset), p-dimethylaminobenzaldehyde (Sigma Chemi-
cal Co., Poole, Dorset) and triple distilled water were used.
Other reagents were of analytical grade.
Sample collection Blood samples from three normal mice at
each time point were taken by cardiac puncture under ether
anaesthesia, collected into heparanised tubes, centrifuged at
2,000g and 4°C for 10min and then separated plasma stored
at -20°C until analysis.
Drug was removed from the peritoneum by three 5 ml
washes with acetate buffer (0.IM, pH4.0). Peritoneal volume
was determined prior to washing at each time point by
Evans blue dilution. This volume was used to calculate drug
concentrations.
Sample extraction and chromatography LM985 and LM975
were extracted from fluid samples using solid phase
chromatography and measured by an HPLC method
described by Double et al. (1986) and modified from Kerr et
al. (1985).
Standard curves were prepared by the addition of LM985
and LM975 to buffered control mouse plasma (pH4.0) and
plotting ratio of peak areas of LM985 and LM975 to the
internal standard against drug concentration. Peaks were
traced and integrated with an Isaac Model 42A data module
(Cyborg Corporation, USA). An Apple IIE computer (Apple
Computer, Inc., USA) and Appligration II software
(Dynamic Solutions Corporation, USA). The curves were
linear over the range 0.1-40pgml-1. The assay was sensitive
to drug concentration of lOngnml-1. Recovery was >90%
for both compounds.
In vitro stability studies RPMI 1640 (2ml) with a concen-
tration of 1 mgkg-I LM985 was incubated at 37°C. Samples
were taken and immediately diluted 1/1(v/v) with acetate
buffer and 100p1 of internal standard were immediately
added. LM985 and LM975 were then extracted as described
(Double et al., 1986). This procedure was repeated with
0.9% physiological saline instead of RPMI.
Protein binding
LM975 was added at various concentrations to PBS as
control, RPMI 1640 containing 10% FCS, human plasma
and mouse plasma. The mixtures were incubated for 1 hr at
37°C and aliquots taken for ultra filtration using a multi-
micro concentrator (Amicon, MA, USA) and Amicon PMIO
Diaflo membranes (25mm diameter). The ultrafiltrates were
then analysed by HPLC and protein binding (PB) calculated
from:
PB= I concentration in matrix ultrafiltrate 100%
concentration in PBS ultrafiltrate
Pharmacokinetic analysis The area under the concentration
versus time curve (AUC) was calculated using the trapezoid
rule.
Results
In vivo anti-tumour activity ofLM975
The i.p. maximum tolerated dose of LM975 in NMRI mice
was 300mgkg-1. The compound had no effect against MAC
15A ascites tumours (Table I). Single dose treatment against
MAC 13 produces some tumour inhibition but this is
considerably enhanced by repeat treatment (Table II).
Greater than 90% tumour inhibition can be achieved at
300mgkg-1 on day 2 and day 9 with no indication of
toxicity. Similar responses are seen with the slower growing
MAC 26 tumours with cures being achieved with
300mgkg-1 on day 0 and day 7 (Figure 2).
In vitro chemosensitivity
MAC 13 cells grown in vitro are sensitive to LM985 but
MAC 15A cells are much less responsive (Figure 3). In vitro
chemosensitivity data of MAC 13 cells to LM975 are
presented in Figure 4. Two hour exposure to doses of up to
2mgml-1 of LM975 fail to produce a response in MAC
15A cells (Figure 5). Longer exposure times result in signifi-
Table I Activity of LM975 against MAC 15A
Dose (mgkg 1) Vehicle T/C% Activity
600 0.9% saline 7 Toxic
300 0.9% saline 100 0
200 0.9% saline 107 0
100 0.9% saline 107 0
Positive control Ethanol/
Methyl-CCNU Arachis oil
20 (1/10) 154 1 +
ControlANTI-TUMOUR ACTIVITY OF LM985 AND LM975 161
Table II Activity of LM975 against MAC 13
Dose (mgkg-1)
Day 2 Day 9 Vehicle Survivors T/C% Activity
600 - 0.9% saline 0/10
300 - 0.9% saline 10/10 51 1+
300 300 0.9% saline 10/10 4 4+
200 - 0.9% saline 10/10 57 1+
200 200 0.9% saline 10/10 10 3+
100 - 0.9% saline 10/10 79 0
100 100 0.9% saline 10/10 43 2+
Positive control Ethanol/
Methyl-CCNU Arachis oil
20 (1/10) 10/10 4 4+
Control Ethanol/ 10/10
Arachis oil
(1/10)
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Figure 3 In vitro chemosensitivity of
cells to LM985.
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Figure 2 Activity of LM975 against MAC 26 (- untreated
control, *-0 200mgkg-1 day 0, O O 200mgkg-1 day 0,
day 7, *-* 300mgkg- I day 0, 0-0 300 mgkg-1 day 0, day
7, AL-A positive control compound, cyclophosphamide
300mgkg 1).
Table III LM975 protein binding in various matrices
% Protein binding
Matrix 0.25mgml-1 0.5mgml- 1I.Omgml-' 2.0mgml-
PBS 0 0 0 0
RPMI 1640
+10% FCS 0 0 0 0
Human plasma 81 82 57 77
Mouse plasma 47 61 61 44
cant anti-tumour effects. Degradation studies of LM985 in
tissue culture fluid are described in Figure 6. LM985 was
stable for at least 5 h in 0.9% saline and ethanol and for 3
days in acetate buffer (pH4.0).
Analysis of protein binding of LM975 in PBS, supple-
mented RPMI 1640, human and mouse plasma is described
in Table III.
MAC 13 and MAC 15A
h
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Figure 4 In vitro chemosensitivity of MAC 13 cells to LM975 at
a range of exposure times and concentration.
Peritoneal levels of LM985 and LM975 following i.p.
inoculation of 3 dose levels of LM985 are presented in
Figure 7. Both LM985 and LM975 are rapidly cleared from
the peritoneum. Levels of LM975 in the peritoneum and
plasma following i.p. inoculation of three dose levels are
described in Figure 8. Identical curves were produced when
these measurements were repeated 7 days later.
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Figure 6 Breakdown of LM985 in tissue culture fluid at 37°C
and at a concentration of 1.0mgml- . Rate of reaction=
13.3imolmin-1.
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Figure 5 In vitro chemosensitivity of MAC 15A cells to LM975
at a range of exposure times and concentration.
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Figure 7 Levels of LM985 (0-0) and LM975 (0-0) in the peritoneum following i.p. administration of three dose levels of
LM985: (a) 400mgkg-1; (b) 200mgkg-1; (c) lOOmgkg-1.
(a)
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(c)
AUC+ I s.d. (mghml-1)
LM985 LM975
2.98+0.31 1.18+0.12
1.22+0.16 0.53+0.07
0.32+0.04 0.20+0.015
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Figure 8 Levels of LM975 (±s.d.) in the peritoneum (closed
symbols) and plasma (open symbols) following i.p. adminis-
tration of three dose levels 0,0 300mgkg-1; *,O
200mgkg-1; A,A 100mgkg-1.
AUC+1 s.d. (mghml1)
Dosemgkg- peritoneum plasma
300 3.21 +0.67 2.52+0.15
200 1.46+0.22 1.83+0.13
100 0,62+0.09 0.89+0.09
Discussion
Initial chemotherapy experiments using the MAC series of
transplantable adenocarcinomas of the colon (Double et al.,
1986) have demonstrated that 2 s.c. tumours of different
histology and growth characteristics (MAC 13 and MAC 26)
respond to LM985. The ascitic line MAC 15A was
unresponsive.
This study demonstrates that MAC 13 is highly sensitive
to LM985 in vitro whereas MAC 15A cells are only
moderately sensitive at a 1 h exposure. LM985 degrades to
LM975 in tissue culture medium at a rate similar to that
previously shown for degradation in human plasma. There
was no evidence of any protein binding to the serum in
complete tissue culture medium. Analysis of peritoneal levels
following i.p. administration of LM985 indicate that LM985
degrades rapidly to LM975 in the peritoneum, MAC 15A
cells in vivo are therefore not exposed to the minimum
LM985 concentration and exposure time required to effect a
response. Kerr et al. (1986) have completed a Phase I clinical
trial with LM985 and are currently conducting a similar trial
with LM975. They state that higher doses of LM975 can be
given without dose limiting toxicity and probably without
loss of anti-tumour activity. The in vivo responses achieved
here with MAC 13 and MAC 26 confirm LM975 to be
highly active against s.c. mouse tumours. The lack of
response of the ascites tumour MAC 15A to LM975 in vivo
is more interesting as analysis of LM975 in the peritoneum
following i.p. administration reveals high levels for the first
30min.
In vitro chemosensitivity studies show that MAC 15A cells
are in fact less responsive to LM975 than LM985. They are
unresponsive to 2h exposures of concentration of up to
2mgml-1 but long term exposures result in improved cyto-
toxicity. The concentrations and exposure times experienced
by MAC 15A tumours grown in vivo are therefore
insufficient to produce a response. Comparison of in vitro
assays with LM975 and LM985 indicate the parent
compound to be considerably more active against MAC 13
than the hydrolysis product. Long term exposures to LM975
in vitro result in improved cytotoxicity.
In conclusion this study reveals that LM975 is less active
in vitro than LM985 but that in vitro chemosensitivity to
LM975 increases with prolonged exposures. Dose response
curves show the minimum drug concentrations and exposure
times required to effect a response in vitro and would suggest
that if these parameters are achievable in vivo the tumour
would respond. Pharmacokinetic studies have indicated the
plasma levels necessary to achieve a response in sub-
cutaneous tumours, and these levels are lower than those
predicted in the MAC 13 in vitro assays. Protein binding
studies of LM975 in mouse and human plasma have indi-
cated moderate binding. The reasons for the apparent
difference in chemosensitivity between in vitro and in vivo
tumours are under investigation.
From Table II the more than additive percentage cell kill
produced by the second injection is difficult to explain, as
this phenomenon has never been observed with standard
agents in this tumour system. The cures seen in MAC 26
have never previously been achieved. The measurement of
pharmacokinetic parameters provide no explanation for the
dramatic tumour responses achieved by repeated treatment
as these were identical for mice treated at days 2 and 9. This
phenomenon will be the subject offurther investigation.
The MAC series of tumours has previously been shown to
be a good model of human disease with responses to
standard agents only seen close to maximum tolerated dose
(Double & Ball, 1975). Similar anti-tumour responses may
well be achieved in human large bowel cancer if the
minimum drug concentrations and exposure times presented
here can be achieved in man.
This work was supported by the Whyte Watson/Turner Cancer
Research Trust, Bradford.
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